Obesity and breast cancer outcomes in chemotherapy patients in New Zealand – a population-based cohort study

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  P. Bernard,et al.  Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer , 2017, Cancer.

[3]  M. McCullough,et al.  Abstract 3008: Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the CPS-II Nutrition Cohort , 2017 .

[4]  Z. Bago-Horvath,et al.  The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. , 2017, Breast.

[5]  G. Body,et al.  Indice de masse corporelle et facteurs pronostiques du cancer du sein , 2017 .

[6]  M. Strother,et al.  Body mass index (BMI): association with clinicopathological factors and outcome of women with newly diagnosed breast cancer in New Zealand. , 2017, The New Zealand medical journal.

[7]  S. Tin Tin,et al.  Missing data on body mass index in a breast cancer register: how is it associated with patient characteristics and clinical outcomes? , 2017, The New Zealand medical journal.

[8]  S. Ahn,et al.  Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer , 2017, PloS one.

[9]  B. Son,et al.  Abstract P6-09-38: Interaction between body mass index and hormone receptor status as a prognostic factor in node-positive breast cancer , 2017 .

[10]  X. Shu,et al.  Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors , 2016, Breast Cancer Research and Treatment.

[11]  E. John,et al.  Racial and ethnic disparities in the impact of obesity on breast cancer risk and survival: a global perspective. , 2015, Advances in nutrition.

[12]  Benjamin D. L. Li,et al.  Breast cancer outcomes in a population with high prevalence of obesity. , 2015, The Journal of surgical research.

[13]  M. Beckmann,et al.  The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial , 2015, Breast Cancer Research.

[14]  D. Berry,et al.  Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). , 2015, Journal of the National Cancer Institute.

[15]  J. Manson,et al.  Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. , 2015, JAMA oncology.

[16]  Christoph Scholz,et al.  Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer , 2015, Breast Cancer Research and Treatment.

[17]  I. Stijleman,et al.  Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression , 2015, BMC Cancer.

[18]  A. Leitch,et al.  Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer , 2015, Cancer medicine.

[19]  N. Scott,et al.  Accuracy and completeness of the New Zealand Cancer Registry for staging of invasive breast cancer. , 2014, Cancer epidemiology.

[20]  Clémence Bussière,et al.  The Effects of Obesity and Mobility Disability in Access to Breast and Cervical Cancer Screening in France: Results from the National Health and Disability Survey , 2014, BMC Health Services Research.

[21]  D. Porter,et al.  Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review , 2014, Breast Cancer Research and Treatment.

[22]  M. Miyazaki,et al.  The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients. , 2014, Breast.

[23]  C. Villarreal-Garza,et al.  Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients , 2014, Breast Cancer Research and Treatment.

[24]  N. Pearce,et al.  Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices. , 2014, Journal of clinical epidemiology.

[25]  A. McTiernan,et al.  Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  O. Nanni,et al.  Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[27]  R. Greil,et al.  The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial , 2013, British Journal of Cancer.

[28]  P. Porter,et al.  Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population , 2013, Cancer Causes & Control.

[29]  X. Shu,et al.  Weight Change and Survival after Breast Cancer in the After Breast Cancer Pooling Project , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[30]  R. Kay.  The Analysis of Survival Data , 2012 .

[31]  J. Griggs,et al.  Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2012, Journal of oncology practice.

[32]  X. Shu,et al.  Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project , 2012, Breast Cancer Research and Treatment.

[33]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[34]  C. Ulrich,et al.  Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Wolff,et al.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. , 2008, JAMA.

[36]  J. Griggs,et al.  Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  I. G. Fantus,et al.  Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Griggs,et al.  Undertreatment of obese women receiving breast cancer chemotherapy. , 2005, Archives of internal medicine.

[39]  E. Mamounas,et al.  Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. , 2003, Journal of the National Cancer Institute.

[40]  S. Cummings,et al.  Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  David E. Booth,et al.  Analysis of Incomplete Multivariate Data , 2000, Technometrics.

[42]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[43]  A. Miller,et al.  Pre‐morbid body size and the prognosis of women with breast cancer , 1994, International journal of cancer.

[44]  A. Miller,et al.  Premorbid diet and the prognosis of women with breast cancer. , 1994, Journal of the National Cancer Institute.

[45]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[46]  P. Grambsch,et al.  Martingale-based residuals for survival models , 1990 .

[47]  L. Kuller,et al.  The epidemiology of serum sex hormones in postmenopausal women. , 1989, American journal of epidemiology.

[48]  S. Graham,et al.  Dietary fat consumption and survival among women with breast cancer. , 1985, Journal of the National Cancer Institute.

[49]  R. Doll,et al.  Body size and survival in premenopausal breast cancer. , 1985, British Journal of Cancer.

[50]  B. Esmaeli,et al.  Change in Eyelid Carcinoma T Category With Use of the 8th Versus 7th Edition of the American Joint Committee on Cancer: Cancer Staging Manual. , 2019, Ophthalmic plastic and reconstructive surgery.

[51]  M. McCullough,et al.  Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort , 2017, Breast Cancer Research and Treatment.

[52]  A. Engin.  Obesity-associated Breast Cancer: Analysis of risk factors. , 2017, Advances in experimental medicine and biology.

[53]  C. Diguisto,et al.  [Outcomes of patients with breast cancer in function of their body mass index]. , 2017, Gynecologie, obstetrique, fertilite & senologie.

[54]  B. Henderson,et al.  Obesity and mortality after breast cancer by race/ethnicity: The California Breast Cancer Survivorship Consortium. , 2014, American journal of epidemiology.

[55]  M. Ewertz,et al.  Effect of obesity on prognosis after early-stage breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.